Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$11.27 – $20.16
16% from low
Exchange
OTC Link
ADRC
Borrow rate
0.25%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $20.89B | $24.23B | $23.65B | $26.86B | $26.03B | $26.20B | $28.87B | $30.97B |
| Cost of revenue | $4.20B | $4.93B | $5.18B | $5.33B | $5.80B | $4.99B | $5.34B | $5.55B |
| Gross profit | $16.69B | $19.31B | $18.46B | $21.53B | $21.54B | $21.21B | $23.53B | $25.41B |
| Gross margin | 79.9% | 79.7% | 78.1% | 80.1% | 82.8% | 81.0% | 81.5% | 82.1% |
| R&D | $2.09B | $2.40B | $2.63B | $3.75B | $4.33B | $4.47B | $5.23B | $5.71B |
| Operating income | $4.97B | $5.81B | $4.19B | $5.08B | $5.59B | $5.79B | $6.14B | $6.63B |
| EBITDA | $6.15B | $7.37B | $5.66B | $19.87B | $6.69B | $6.98B | $6.11B | $7.78B |
| Net income | $9.05B | $4.69B | $2.77B | $14.61B | $2.54B | $2.33B | $3.50B | $2.28B |
| Net margin | 43.3% | 19.4% | 11.7% | 54.4% | 9.8% | 8.9% | 12.1% | 7.4% |
| EPS (diluted) | 9.80 | 5.00 | 3.00 | 14.60 | 2.40 | 1.99 | 3.80 | 2.60 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $36.0B | $0.00 | $0.00–$0.00 | 0 |
| 2027 | $39.1B | $0.00 | $0.00–$0.00 | 0 |
Forward consensus · source: Financial Modeling Prep
SINO BIOPHARM UNSP/ADR
No one on the platform currently holds SBHMY.
No tracked institution reports a position in SBHMY as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-06-25 | $0.1276 | 2026-08-04 |
| 2025-08-29 | $0.1286 | 2025-10-08 |
| 2025-06-17 | $0.1019 | 2025-07-25 |
| 2024-09-11 | $0.0772 | 2024-10-18 |
| 2024-06-12 | $0.0768 | 2024-07-22 |
| 2023-10-04 | $0.0511 | 2023-11-13 |
| Execution date | Ratio |
|---|---|
| 2020-08-14 | 1.5-for-1 |
| 2018-06-26 | 3-for-2 |
No one on the platform has traded SBHMY yet.
| $16.9B |
| — |
| IVBXFInnovent Biologics, Inc. | $11.03 | +7.36% | $19.1B | — |
| ORINYOrion Oyj | $41.27 | +9.09% | $23.2B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 4.4× earnings vs its 4.6× historical median P/E.
Fair value ≈ $13.31 · price $12.68 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.